Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
21st Century Cures Act
Client: CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP · Firm: THE CONAFAY GROUP, LLC
H.R. 6: 21st Century Cures Act Provisions related to DISARM and LPAD
H.R. 6 - 21st Century Cures Act FDA Reform
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2026 · first_quarter · Q1
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY27 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2025 · fourth_quarter · Q4
Source: Senate LDA
| PARATEK PHARMACEUTICALS, INC. |
| 5 |
| 2023 |
| WCG WIRB COPERNICUS GROUP | 5 | 2016 |
| ATEA PHARMACEUTICALS, INC. | 4 | 2023–2024 |
| BANNER LIFE SCIENCES | 3 | 2015 |
| CIDARA THERAPEUTICS INC | 3 | 2020 |
| DOVA PHARMACEUTICALS | 3 | 2018 |
| PHLOW CORPORATION | 3 | 2020 |
| WOODBERRY & ASSOCIATES ON BEHALF OF COLORADO STATE UNIVERSITY FOUNDATION | 3 | 2014 |
| LYSOVANT SCIENCES INC. | 2 | 2019 |
| CARY PHARMACEUTICALS | 1 | 2012 |
| CONAFAY GROUP LLC ON BEHALF OF MEDICAGO | 1 | 2014 |
| FOUNDATION FIGHTING BLINDNESS | 1 | 2023 |
| MID-ATLANTIC BIOTHERAPEUTICS | 1 | 2017 |
21st Century Cures Act
Client: CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP · Firm: THE CONAFAY GROUP, LLC
H.R. 6: 21st Century Cures Act Provisions related to DISARM and LPAD
H.R. 6 - 21st Century Cures Act FDA Reform
21st Century Cures Act
Client: CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP · Firm: THE CONAFAY GROUP, LLC
H.R. 6: 21st Century Cures Act Provisions related to DISARM and LPAD
H.R. 6 - 21st Century Cures Act FDA Reform
H.R. 6 - 21st Century Cures Act FDA Reform
21st Century Cures Act
Client: CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP · Firm: THE CONAFAY GROUP, LLC
H.R. 6: 21st Century Cures Act Provisions related to DISARM and LPAD
H.R. 6 - 21st Century Cures Act Developing a range of tissue and disease models for medical research and therapeutics applications.
21st Century Cures Act
Client: CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP · Firm: THE CONAFAY GROUP, LLC
H.R. 6: 21st Century Cures Act Provisions related to DISARM and LPAD
21st Century Cures Act
Client: CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP · Firm: THE CONAFAY GROUP, LLC
H.R. 6: 21st Century Cures Act Provisions related to DISARM and LPAD
H.R. 6 - 21st Century Cures Act Developing a range of tissue and disease models for medical research and therapeutics applications
21st Century Cures Act
Client: CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP · Firm: THE CONAFAY GROUP, LLC
H.R. 6 21st Century Cures Act Provisions related to DISARM and LPAD
H.R. 6 - 21st Century Cures Act FDA Reform
H.R. 6 - 21st Century Cures Act FDA Reform
H.R. 6 - 21st Century Cures Act FDA Reform
H.R. 6 - 21st Century Cures Act Developing a range of tissue and disease models for medical research and therapeutics applications.
H.R. 6 - 21st Century Cures Act Developing a range of tissue and disease models for medical research and therapeutics applications
H.R. 6 - 21st Century Cures Act FDA Reform
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY26 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2025 · third_quarter · Q3
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY26 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2025 · second_quarter · Q2
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY26 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2025 · first_quarter · Q1
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY26 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2024 · fourth_quarter · Q4
Legislation related to antimicrobial resistance(AMR), reimbursement reform, CURES Act 2.0 and FY25 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2024 · third_quarter · Q3
Legislation related to antimicrobial resistance(AMR), reimbursement reform, the PASTEUR Act, Cares Act 2.0 and FY25 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ATEA PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2024 · second_quarter · Q2
Support for medical/disease research.
Support for medical/disease research.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2024 · second_quarter · Q2
Legislation related to antimicrobial resistance(AMR), reimbursement reform, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ATEA PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Support for medical/disease research.
Support for medical/disease research.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2024 · first_quarter · Q1
Legislation related to antimicrobial resistance(AMR), reimbursement reform, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Legislation related to antimicrobial resistance(AMR), reimbursement reform, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ATEA PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · Q4
Support for medical/disease research.
Support for medical/disease research.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PARATEK PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2023 · fourth_quarter · 4T
Procurement of novel antibiotic.
Procurement of novel antibiotic.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PARATEK PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Procurement of novel antibiotic.
Procurement of novel antibiotic.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
ATEA PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2023 · third_quarter · Q3
Support for medical/disease research.
Support for medical/disease research.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2023 · second_quarter · Q2
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PARATEK PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2023 · second_quarter · Q2
Procurement of novel antibiotic.
Procurement of novel antibiotic.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
PARATEK PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2023 · first_quarter · Q1
Procurement of novel antibiotic.
Procurement of novel antibiotic.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE
FOUNDATION FIGHTING BLINDNESS via THE CONAFAY GROUP, LLC
2023 · first_quarter · Q1
Education & advocacy for mechanisms to spur development of clinical trials.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2023 · first_quarter · Q1
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cares Act 2.0 and FY24 Appropriations and PAHPA.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PARATEK PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2023 · first_quarter · RR
Support for medical/disease research and advocacy.
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2022 · fourth_quarter · Q4
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cares Act 2.0 and COVID19 response packages.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2022 · third_quarter · Q3
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cares Act 2.0 and COVID19 response packages.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2022 · second_quarter · Q2
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cares Act 2.0 and COVID19 response packages.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2022 · first_quarter · Q1
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cares Act 2.0 and COVID19 response packages.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2021 · fourth_quarter · Q4
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cares Act 2.0 and COVID19 response packages.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2021 · third_quarter · Q3
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cares Act 2.0 and COVID19 response packages.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2021 · second_quarter · Q2
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cares Act 2.0 and COVID19 response packages.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2021 · first_quarter · Q1
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cares Act 2.0 and COVID19 response packages.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2020 · fourth_quarter · Q4
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cures 2.0 and COVID19 response packages.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CIDARA THERAPEUTICS, INC. via THE CONAFAY GROUP, LLC
2020 · third_quarter · Q3
Support for research on viral diseases
Support for research on viral diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2020 · third_quarter · Q3
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cures 2.0 and COVID19 response packages.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CIDARA THERAPEUTICS, INC. via THE CONAFAY GROUP, LLC
2020 · second_quarter · Q2
Support for research on viral diseases
Support for research on viral diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHLOW CORPORATION via THE CONAFAY GROUP, LLC
2020 · second_quarter · 2T
US pharmaceutical manufacturing
US pharmaceutical manufacturing
US pharmaceutical manufacturing
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2020 · second_quarter · Q2
Legislation related to antimicrobial resistance(AMR), the DISARM Act, the PASTEUR Act, Cures 2.0 and COVID19 response packages.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2020 · first_quarter · Q1
Legislation related to DISARM and biologics.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CIDARA THERAPEUTICS, INC. via THE CONAFAY GROUP, LLC
2020 · first_quarter · Q1
Support for research on viral diseases
Support for research on viral diseases
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHLOW CORPORATION via THE CONAFAY GROUP, LLC
2020 · first_quarter · Q1
US pharmaceutical manufacturing
US pharmaceutical manufacturing
US pharmaceutical manufacturing
PHLOW CORPORATION via THE CONAFAY GROUP, LLC
2020 · first_quarter · RR
US Pharmaceutical Manufacturing
US Pharmaceutical Manufacturing
US Pharmaceutical Manufacturing
US Pharmaceutical Manufacturing
LYSOVANT SCIENCES INC. via THE CONAFAY GROUP, LLC
2019 · fourth_quarter · Q4
Possible BARDA Appropriations.
Filing targets: Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2019 · fourth_quarter · Q4
Legislation related to DISARM and R&D tax credit and biologics.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
LYSOVANT SCIENCES INC. via THE CONAFAY GROUP, LLC
2019 · fourth_quarter · RR
Reimbursement reform.
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2019 · third_quarter · Q3
Legislation related to DISARM and R&D tax credit and biologics.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2019 · second_quarter · 2A
Legislation related to DISARM and R&D tax credit and biologics.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2019 · second_quarter · Q2
Legislation related to DISARM and R&D tax credit and biologics.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2019 · first_quarter · Q1
Legislation related to DISARM and R&D tax credit and biologics.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CHIESI USA, INC. via THE CONAFAY GROUP, LLC
2018 · fourth_quarter · 4T
Advocacy for medical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via THE CONAFAY GROUP, LLC
2018 · fourth_quarter · Q4
Advocacy for medical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2018 · fourth_quarter · Q4
Legislation related to DISARM and R&D tax credit and biologics.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CHIESI USA, INC. via THE CONAFAY GROUP, LLC
2018 · third_quarter · Q3
Advocacy for medical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DOVA PHARMACEUTICALS via THE CONAFAY GROUP, LLC
2018 · third_quarter · Q3
Advocating for medical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2018 · third_quarter · Q3
Legislation related to DISARM and R&D tax credit and biologics.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CHIESI USA, INC. via THE CONAFAY GROUP, LLC
2018 · second_quarter · Q2
Advocacy for medical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DOVA PHARMACEUTICALS via THE CONAFAY GROUP, LLC
2018 · second_quarter · Q2
Advocating for medical research.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2018 · second_quarter · Q2
Legislation related to DISARM and R&D tax credit.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
DOVA PHARMACEUTICALS via THE CONAFAY GROUP, LLC
2018 · second_quarter · RR
Advocating for medical research.
CHIESI USA, INC. via THE CONAFAY GROUP, LLC
2018 · second_quarter · RR
Advocacy for medical research.
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2018 · first_quarter · Q1
Legislation related to DISARM and R&D tax credit.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2017 · fourth_quarter · Q4
Legislation related to DISARM and R&D tax credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CEMPRA PHARMACEUTICALS via THE CONAFAY GROUP, LLC
2017 · fourth_quarter · 4T
FDA Reform
Medicare policies involving antibiotics to treat resistant pathogens.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
MID-ATLANTIC BIOTHERAPEUTICS via THE CONAFAY GROUP, LLC
2017 · third_quarter · Q3
Seeking support for rabies research.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES
CEMPRA PHARMACEUTICALS via THE CONAFAY GROUP, LLC
2017 · third_quarter · Q3
FDA Reform
Medicare policies involving antibiotics to treat resistant pathogens.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2017 · third_quarter · Q3
Legislation related to DISARM and R&D tax credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CEMPRA PHARMACEUTICALS via THE CONAFAY GROUP, LLC
2017 · second_quarter · Q2
FDA Reform
Medicare policies involving antibiotics to treat resistant pathogens.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2017 · second_quarter · 2T
General legislation pertaining to the improvement of the healthcare system to provide access to Medicare and Medicaid.
General legislation pertaining to the improvement of the healthcare system to provide access to Medicare and Medicaid; PDUFA Reauthorization.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2017 · second_quarter · Q2
Legislation related to DISARM and R&D tax credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CEMPRA PHARMACEUTICALS via THE CONAFAY GROUP, LLC
2017 · first_quarter · Q1
FDA Reform
Medicare policies involving antibiotics to treat resistant pathogens.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2017 · first_quarter · Q1
General legislation pertaining to the improvement of the healthcare system to provide access to Medicare and Medicaid; PDUFA Reauthorization.
General legislation pertaining to the improvement of the healthcare system to provide access to Medicare and Medicaid.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2017 · first_quarter · Q1
Legislation related to DISARM and R&D tax credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2016 · fourth_quarter · Q4
Improvement to the healthcare system to provide access to Medicare and Medicaid, 21st Century Cures discussion.
Improvement to the healthcare system to provide access to Medicare and Medicaid, 21st Century Cures discussion.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2016 · fourth_quarter · Q4
H.R. 6: 21st Century Cures Act Provisions related to DISARM and LPAD
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WCG WIRB COPERNICUS GROUP via THE CONAFAY GROUP, LLC
2016 · fourth_quarter · Q4
21st Century Cures legislation.
21st Century Cures legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CEMPRA PHARMACEUTICALS via THE CONAFAY GROUP, LLC
2016 · fourth_quarter · Q4
Medicare policies involving antibiotics to treat resistant pathogens.
H.R. 6 - 21st Century Cures Act FDA Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CEMPRA PHARMACEUTICALS via THE CONAFAY GROUP, LLC
2016 · third_quarter · Q3
Medicare policies involving antibiotics to treat resistant pathogens.
H.R. 6 - 21st Century Cures Act FDA Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2016 · third_quarter · Q3
Improvement to the healthcare system to provide access to Medicare and Medicaid, 21st Century Cures discussion.
Improvement to the healthcare system to provide access to Medicare and Medicaid, 21st Century Cures discussion.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
WCG WIRB COPERNICUS GROUP via THE CONAFAY GROUP, LLC
2016 · third_quarter · Q3
21st Century Cures legislation.
21st Century Cures legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2016 · third_quarter · Q3
H.R. 6: 21st Century Cures Act Provisions related to DISARM and LPAD
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CEMPRA PHARMACEUTICALS via THE CONAFAY GROUP, LLC
2016 · second_quarter · Q2
Medicare policies involving antibiotics to treat resistant pathogens.
H.R. 6 - 21st Century Cures Act FDA Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2016 · second_quarter · Q2
Improvement to the healthcare system to provide access to Medicare and Medicaid, 21st Century Cures discussion.
Improvement to the healthcare system to provide access to Medicare and Medicaid, 21st Century Cures discussion.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2016 · second_quarter · Q2
H.R. 6: 21st Century Cures Act Provisions related to DISARM and LPAD
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WCG WIRB COPERNICUS GROUP via THE CONAFAY GROUP, LLC
2016 · second_quarter · Q2
21st Century Cures legislation.
21st Century Cures legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WCG WIRB COPERNICUS GROUP via THE CONAFAY GROUP, LLC
2016 · first_quarter · Q1
21st Century Cures legislation.
21st Century Cures legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2016 · first_quarter · Q1
H.R. 6: 21st Century Cures Act Provisions related to DISARM and LPAD
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CEMPRA PHARMACEUTICALS via THE CONAFAY GROUP, LLC
2016 · first_quarter · Q1
Medicare policies involving antibiotics to treat resistant pathogens.
H.R. 6 - 21st Century Cures Act FDA Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2016 · first_quarter · Q1
Improvement to the healthcare system to provide access to Medicare and Medicaid, 21st Century Cures discussion.
Improvement to the healthcare system to provide access to Medicare and Medicaid, 21st Century Cures discussion.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ORGANOVO, INC. via THE CONAFAY GROUP, LLC
2016 · first_quarter · 1T
H.R. 6 - 21st Century Cures Act Developing a range of tissue and disease models for medical research and therapeutics applications.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WCG WIRB COPERNICUS GROUP via THE CONAFAY GROUP, LLC
2016 · first_quarter · RR
21st Century Cures Legislation
21st Century Cures Legislation
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2015 · fourth_quarter · Q4
H.R. 6: 21st Century Cures Act Provisions related to DISARM and LPAD
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CEMPRA PHARMACEUTICALS via THE CONAFAY GROUP, LLC
2015 · fourth_quarter · Q4
Medicare policies involving antibiotics to treat resistant pathogens.
H.R. 6 - 21st Century Cures Act FDA Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOVO, INC. via THE CONAFAY GROUP, LLC
2015 · fourth_quarter · Q4
H.R. 6 - 21st Century Cures Act Developing a range of tissue and disease models for medical research and therapeutics applications.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2015 · fourth_quarter · Q4
Improvement to the healthcare system to provide access to Medicare and Medicaid, 21st Century Cures discussion.
Improvement to the healthcare system to provide access to Medicare and Medicaid, 21st Century Cures discussion.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
BANNER LIFE SCIENCES via THE CONAFAY GROUP, LLC
2015 · third_quarter · 3T
Appropriate funds for pharmaceutical research and development.
Appropriate funds for pharmaceutical research and development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ORGANOVO, INC. via THE CONAFAY GROUP, LLC
2015 · third_quarter · Q3
H.R. 6 - 21st Century Cures Act Developing a range of tissue and disease models for medical research and therapeutics applications
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CEMPRA PHARMACEUTICALS via THE CONAFAY GROUP, LLC
2015 · third_quarter · Q3
Medicare policies involving antibiotics to treat resistant pathogens
H.R. 6 - 21st Century Cures Act FDA Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ALNYLAM PHARMACEUTICALS, INC. via THE CONAFAY GROUP, LLC
2015 · third_quarter · Q3
Improvement to the healthcare system to provide access to Medicare and Medicaid, 21st Century Cures discussion
Improvement to the healthcare system to provide access to Medicare and Medicaid, 21st Century Cures discussion
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CONAFAY GROUP ON BEHALF OF ANTIBIOTICS WORKING GROUP via THE CONAFAY GROUP, LLC
2015 · third_quarter · Q3
H.R. 6: 21st Century Cures Act Provisions related to DISARM and LPAD
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BANNER LIFE SCIENCES via THE CONAFAY GROUP, LLC
2015 · second_quarter · Q2
Appropriate funds for pharmaceutical research and development.
Appropriate funds for pharmaceutical research and development.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BANNER LIFE SCIENCES via THE CONAFAY GROUP, LLC
2015 · first_quarter · RR
Appropriate funds for pharmaceutical research and development
Appropriate funds for pharmaceutical research and development
US pharmaceutical manufacturing
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
US pharmaceutical manufacturing
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE